| Category | BioTech |
| Employees |
| TOTAL | $31M |
| VENTURE FUNDING TOTAL | $31M |
| Series A, 1/13 venBio Canaan Partners InterWest Partners Sofinnova Ventures | $31M |
Labrys Biologics Inc., a company focused on treatments for chronic migraine.
Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.
RN-307 was originally developed by Rinat Pharmaceuticals, acquired by Pfizer in 2006.
